Vassiliki Papadimitrakopoulou
Medical Oncology · Houston, TXNPI 1144311101
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by AstraZeneca at 38.1% of the total.
Across 53 payments — averaging $772.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$16K
- F. Hoffmann-la Roche AG$8K
- Bayer$6K
- Merck$3K
- Astrazeneca UK Limited$3K
- Janssen Global Services, LLC$2K
- plus $3K from 3 others
Across 49 payments — averaging $57,288 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$1.2M
- Novartis$892K
- Merck$230K
- Foundation Medicine, Inc.$182K
- Clovis Oncology, Inc.$169K
- Incyte Corporation$35K
- plus $54K from 2 others
What the payments were for
- Consulting fees$22,98756%
- Speaking & faculty fees$11,06627%
- Travel & lodging$5,66614%
- Food & beverage$1,2223%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 16 | $15,586 |
| F. Hoffmann-la Roche AG | 6 | $7,896 |
| Bayer | 6 | $6,237 |
| Merck | 5 | $3,404 |
| Astrazeneca UK Limited | 4 | $3,040 |
| Janssen Global Services, LLC | 1 | $1,550 |
| Pfizer | 3 | $1,260 |
| Eli Lilly | 9 | $1,035 |
| Genentech USA, Inc. | 3 | $933 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$40,941 in reported general payments places this provider in the 75th percentile of 495 medical oncology providers in Texas.
Other medical oncology in Houston
- Roy HerbstHouston$1.9M
- Maen AbdelrahimHouston$999K
- John HeymachHouston$726K
- Putao CenHouston$720K
- Hagop KantarjianHouston$559K
- Ricardo AlvarezHouston$553K
- Eleni EfstathiouHouston$519K
- Srdan VerstovsekHouston$464K
- Guillermo Garcia-ManeroHouston$454K
- Jason WestinHouston$407K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.